Essen, Germany. Evonik is set to unveil its latest innovations in nutraceutical ingredients at Vitafoods Europe 2024, held in Geneva, Switzerland. Highlighting new concepts such as AvailOm? omega-3 powder combined with Boswellia for joint health, recent study results on IN VIVO BIOTICS?, and the expansion of the Healthberry? portfolio to the U.S. market, Evonik continues to deliver advanced, evidence-based food ingredients designed to enhance consumer preferences and distinguish functional food and supplement brands.
Advanced Nutraceuticals and Coating Technologies
Evonik Health Care’s nutraceutical portfolio features naturally occurring ingredients with scientifically validated health benefits, along with sophisticated nutraceutical coating technologies. These innovations ensure the precise release of health ingredients in the human body. As part of the Nutrition & Care division, Evonik Health Care is committed to improving health and quality of life. The company offers a tailored range of ingredients, coupled with application and formulation expertise, delivering comprehensive system solutions.
Susanne Pluta, Director of Consumer Products at Evonik Health Care, stated, "Through our dedication to research and innovation, we provide customized nutra ingredients that address unique health requirements, enabling our partners to offer their customers a convenient and elevated nutritional experience that enhances their quality of life."
Key Highlights at Vitafoods Europe 2024
AvailOm? Omega-3 Powder and Boswellia Serrata for Joint Health
This innovative concept targets joint health applications, combining Evonik’s advanced formulation expertise with scientific evidence for efficacy. The synergy between AvailOm? omega-3 and Boswellia serrata has been validated through in vitro and human intervention studies, demonstrating their effectiveness.
IN VIVO BIOTICS? Synbiotic Solutions
A recent study highlighted the superior gluten-degrading efficacy of IN VIVO BIOTICS? gluten tolerance, outperforming conventional enzyme-based gluten digestion aids. This underscores the potential of IN VIVO BIOTICS? as a groundbreaking solution in synbiotic formulations.
Expansion of Healthberry? 865/900 to the U.S. Market
Following FDA registration of Evonik’s Norwegian facility, Medpalett, the Healthberry? portfolio is now available in bulk to dietary supplement companies in the U.S. This move facilitates further development and commercialization, broadening the reach of Healthberry? products.
Highlights
- Innovative Joint Health Solutions:AvailOm? omega-3 powder and Boswellia serrata target joint health, backed by scientific studies.
- Advanced Synbiotic Solutions:IN VIVO BIOTICS? demonstrates superior gluten-degrading efficacy in recent studies.
- U.S. Market Expansion:Healthberry? 865/900, now FDA-registered, enters the U.S. market, enhancing product development and availability.
Evonik’s presence at Vitafoods Europe 2024 underscores its commitment to pioneering research and innovative solutions in the nutraceutical industry, aiming to enhance health and quality of life through advanced, evidence-based ingredients.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
